Accera’s Ketasyn™ performed favorably in its Phase II age-associated memory impairment study. A low incidence of adverse events along with statistical significance was achieved for Ketasyn™ as it helped to suppress a loss in memory associated with aging. The Accera pipeline includes therapeutic treatments for Parkinson’s, Alzheimer’s and other age-related memory loss disorders. The products [...]